Last updated: February 24, 2026
What is the Product Corresponding to NDC 00245-0071?
NDC 00245-0071 is designated for Noxafil (posaconazole), an antifungal used primarily for prophylaxis and treatment of invasive fungal infections. It is marketed by Merck & Co. and primarily prescribed for immunocompromised patients, including those undergoing chemotherapy or stem cell transplants.
Market Size and Growth Drivers
Current Market Landscape
- Estimated global antifungal market in 2022: USD 4.2 billion.
- Compound annual growth rate (CAGR) from 2022 to 2027: 8.2% (Research and Markets, 2022).
- Noxafil's share within the antifungal segment is approximately 12%, with revenue around USD 481 million in 2022.
Key Factors Influencing Market Dynamics
- Increased incidence of invasive fungal infections (IFI): Growing immunosuppressed populations elevate demand.
- Expanding use in prophylactic indications: Clinical guidelines favor prophylactic use in neutropenic and transplant patients.
- Emergence of resistant fungal strains: Drives need for potent, broad-spectrum antifungals like posaconazole.
- Pricing trends: Historically premium-priced; price sensitivity varies by healthcare system.
Competitive Landscape
- Key competitors: Mycamine (micafungin), Vfend (voriconazole), and Cresemba (isavuconazole).
- Market penetration for Noxafil remains strong in immunocompromised settings, especially in dedicated oncology and transplant centers.
Price Benchmarks and Revenue Projections
Current Pricing (U.S. Market)
- Average wholesale price (AWP): approximately USD 1,200 per month for a standard prophylactic course (per prescription for a 180-day course, roughly USD 2,400).
- Average selling price (ASP): Estimated at USD 950 to USD 1,050 per month, depending on pharmacy negotiations.
Revenue Projections (2023-2028)
| Year |
Estimated Global Sales (USD Million) |
Assumptions |
| 2023 |
520 |
Stable pricing, increased adoption in emerging markets |
| 2024 |
560 |
Growing awareness, new guideline endorsements |
| 2025 |
610 |
Expansion into additional indications, price rises |
| 2026 |
660 |
Increased penetration in Asia-Pacific |
| 2027 |
720 |
Broader commercialization, patent protection holds |
| 2028 |
780 |
Entry of biosimilars, price erosion begins |
Note: The projections assume modest annual price increases of approximately 3%, offset by potential biosimilar entry starting in 2027.
Patent and Regulatory Status
- Patent expiration: Expected around 2024-2025 globally, with patent cliffs influencing pricing.
- Regulatory developments: Pending approvals for new indications in China and Japan could extend market lifespan and enhance sales.
Pricing Trends and Impact Factors
- Patent cliff expected to prompt price erosion of 15-25% in the U.S. and EU markets starting 2025.
- Launch of biosimilars or generics expected to reduce prices by up to 30-40% within two years.
- Market access and reimbursement policies influence net pricing; payer pressure often limits price growth.
Key Takeaways
- Noxafil’s market remains strong in immunocompromised patient care, with steady growth driven by increasing fungal infection prevalence.
- Price projections indicate gradual increases until patent expiration, after which biosimilar competition will likely erode prices.
- Revenue growth hinges on expanding indications and geographic penetration, particularly in Asia-Pacific regions.
- Biosimilars and generics entering the market circa 2025-2027 will dampen revenue growth and could require strategic repositioning.
FAQs
1. What are the primary therapeutic indications for Noxafil?
Prophylaxis of invasive Aspergillus and Candida infections in immunocompromised patients; treatment of invasive fungal infections caused by Aspergillus spp. and Candida spp.
2. How does the patent landscape affect future pricing?
Patent expiration in 2024-2025 is expected to enable biosimilar entry, likely reducing prices significantly and impacting revenue projections.
3. Which regions provide the highest growth potential?
Emerging markets in Asia-Pacific, particularly China and India, offer potential due to increasing healthcare infrastructure and adoption of antifungal prophylaxis.
4. What factors could accelerate or slow revenue growth?
Emergence of resistance, regulatory delays, approval of new indications, and biosimilar competition are key factors affecting revenue trajectories.
5. How do payer policies influence pricing?
Reimbursement constraints and formulary restrictions limit maximum allowable prices, especially in highly regulated markets like the U.S. and EU, influencing net revenue.
References
- Research and Markets (2022). Global antifungal market analysis, trends & forecasts. Retrieved from [URL].
- Merck & Co. (2022). Noxafil (posaconazole) prescribing information. Retrieved from [URL].
Note: Data and projections herein are based on publicly available market reports, industry trends, and patent timelines as of early 2023.
